Abstract
Dermorphin, a naturally occurring heptapeptide isolated from the skin of amphibians, has been identified as a potent and selective agonist of the μ-opioid receptor (MOR). This compound exhibits remarkable efficacy in inhibiting neuropathic pain, a type of chronic pain often resistant to conventional analgesics. This article reviews the latest research advancements concerning the application of dermorphin in neuropathic pain management, focusing on its pharmacological properties, mechanisms of action, efficacy, and potential clinical applications. The review also discusses the ethical and safety considerations associated with dermorphin use.
Product Code: BM-2-4-003
Name: DERMORPHIN ACETATE
CAS No.: 77614-16-5
Molecular formula: C40H50N8O10
MW: 802.87
EINECS No.: 202-853-6
Enterprise standard: HPLC>99.5%, LC-MS
HS code: Need confirm
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Yinchuan Factory
Technology service: R&D Dept.-3
We provide DERMORPHIN CAS 77614-16-5, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/dermorphin-cas-77614-16-5.html
Keywords: Dermorphin, μ-opioid receptor (MOR), neuropathic pain, analgesics, pharmacological properties
Introduction
Neuropathic pain, characterized by spontaneous pain, hyperalgesia, and allodynia, arises from damage or dysfunction of the somatosensory nervous system. It is a prevalent and debilitating condition that significantly impacts patients' quality of life. Traditional analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, often provide inadequate relief for neuropathic pain. Therefore, there is a pressing need for novel therapeutic agents with enhanced efficacy and fewer side effects. Dermorphin, with its high affinity and selectivity for the MOR, has emerged as a promising candidate for neuropathic pain management.
|
|
|
Pharmacological Properties of Dermorphin
Dermorphin, with the chemical structure of Tyr-{d-Ala}-Phe-Gly-Tyr-Pro-Ser-NH2 (or Y-{d-Ala}-FGYPS-NH2), is a natural heptapeptide discovered in the skin of Phyllomedusa frogs. It possesses a unique chemical structure that confers high affinity and selectivity for the MOR, far exceeding that for the δ-opioid receptor. This specificity makes dermorphin an invaluable tool in neuropharmacological research and a potential therapeutic agent for pain management.
The pharmacological actions of dermorphin are predominantly facilitated through its specific interaction with the mu-opioid receptor (MOR). When dermorphin binds and activates the MOR, it triggers the release of endogenous opioids, like endorphins, which are known for their pain-relieving properties. Furthermore, dermorphin possesses the capability to traverse the blood-brain barrier (BBB). This ability allows it to exert its effects throughout the central nervous system, thereby contributing to its comprehensive analgesic activity, which spans a wide range of pain conditions.
Mechanisms of Action in Inhibiting Neuropathic Pain
The mechanisms underlying dermorphin's inhibition of neuropathic pain are complex and encompass both central and peripheral effects. At the central level, dermorphin targets MORs situated in critical areas such as the brainstem and spinal cord. Here, it modulates nociceptive transmission and enhances descending inhibitory pathways. By activating MORs, dermorphin suppresses the release of neurotransmitters that are pivotal in pain signaling, including glutamate and substance P. Simultaneously, it promotes the release of inhibitory neurotransmitters like gamma-aminobutyric acid (GABA) and enkephalins, which further contribute to reducing pain perception and transmission.
In the peripheral nervous system, dermorphin exhibits direct interactions with MORs present on primary afferent nerve fibers and immune cells. These interactions contribute to decreasing inflammation and nociceptor sensitization, which are key components in the development and maintenance of neuropathic pain. Additionally, dermorphin has demonstrated the capacity to regulate neuroplasticity within the spinal cord and brainstem. This modulation is particularly significant as it helps to reverse the maladaptive changes that are associated with neuropathic pain, thereby facilitating the restoration of normal neural function and pain processing.
|
|
|
Efficacy in Clinical and Preclinical Studies
Preclinical studies utilizing animal models of neuropathic pain have consistently shown dermorphin's effectiveness in alleviating pain-related behaviors, such as mechanical allodynia and thermal hyperalgesia. Specifically, intrathecal administration of dermorphin in rats subjected to sciatic nerve ligation-induced neuropathic pain has demonstrated a dose-dependent analgesic effect. These findings translate well to humans, as dermal application of dermorphin has also been reported to provide relief from neuropathic pain in individuals with peripheral neuropathy. These preclinical and clinical observations highlight dermorphin's potential as a therapeutic agent for managing neuropathic pain.
Clinical studies have further reinforced dermorphin's potential as an analgesic in various pain conditions, including postoperative pain management and cancer-related pain. Notably, dermorphin has exhibited advantages over traditional opioids such as morphine, demonstrating superior efficacy and a more favorable side effect profile. Nonetheless, it is worth noting that the clinical use of dermorphin in neuropathic pain is still in its infancy. Therefore, further studies are needed to determine the optimal dosing regimen, safety profile, and long-term efficacy. These ongoing research efforts are crucial for refining dermorphin's therapeutic application and ensuring its safe and effective use in managing neuropathic pain and other pain conditions.
Potential Clinical Applications
Dermorphin's unique pharmacological properties and proven efficacy in inhibiting neuropathic pain position it as a promising therapeutic option for a wide range of clinical applications. Its potential is particularly notable in patients suffering from refractory neuropathic pain that has not responded to conventional analgesics. Furthermore, dermorphin's ability to cross the blood-brain barrier (BBB) and effectively modulate central nociceptive pathways underscores its potential as a treatment for central neuropathic pain conditions, such as those linked to spinal cord injury or multiple sclerosis. As research progresses, dermorphin may emerge as a valuable addition to the armamentarium of tools available for managing neuropathic pain and improving patients' quality of life.
Additionally, dermorphin's relative absence of significant respiratory depression and other common opioid-related side effects could render it a safer alternative to traditional opioids, particularly for patient populations such as the elderly or those with respiratory comorbidities who may be more susceptible to adverse effects. Nonetheless, further clinical trials are needed to confirm these potential benefits and establish dermorphin's place in the treatment algorithm for neuropathic pain. These trials will be essential for refining dermorphin's therapeutic use, ensuring its safety, and establishing its efficacy in diverse patient populations with neuropathic pain.
Ethical and Safety Considerations
Despite its promising therapeutic potential, the use of dermorphin is not without ethical and safety concerns. Like other opioids, dermorphin has the potential for abuse and addiction. Its ability to produce euphoria and other rewarding effects increases the risk of misuse and dependence. Therefore, strict controls and regulations are necessary to ensure dermorphin's safe and ethical use in clinical practice.
Furthermore, the potential for adverse effects, such as nausea, vomiting, and sedation, should be carefully monitored in patients receiving dermorphin therapy. Long-term use may also be associated with the development of tolerance and withdrawal symptoms, necessitating careful management and monitoring.
Conclusion
Dermorphin, a naturally occurring heptapeptide MOR agonist isolated from amphibian skin, has demonstrated remarkable efficacy in inhibiting neuropathic pain in preclinical and clinical studies. Its unique pharmacological properties, including high affinity and selectivity for the MOR and ability to cross the BBB, contribute to its broad-spectrum analgesic activity. Potential clinical applications include the treatment of refractory neuropathic pain and central neuropathic pain conditions. However, the use of dermorphin is accompanied by ethical and safety considerations, including the risk of abuse and addiction, and potential adverse effects. Further research is needed to establish optimal dosing regimens, safety profiles, and long-term outcomes, ultimately guiding the safe and effective integration of dermorphin into therapeutic algorithms for neuropathic pain management.